Merrimack Pharmaceuticals

Company in Cambridge, United States

Merrimack Pharmaceuticals, Inc.

Company type| Public

Traded as

| Nasdaq: MACK
Russell Microcap Index component
Industry| Pharmaceuticals
Founded| 2000; 25 years ago (2000) in Cambridge, Massachusetts
Headquarters|

Cambridge, Massachusetts

United States

Number of employees

| 426 (2016)
Website| merrimack.com

Merrimack Pharmaceuticals, Inc. is a pharmaceutical company based in Cambridge, Massachusetts, United States. They specialize in developing drugs for the treatment of cancer.

Merrimack's first FDA-approved drug was approved in 2015; Onivyde, a liposome encapsulated version of irinotecan is used for treating pancreatic adenocarcinoma. It was approved for use in the European Union the following year.[1][2]

## History

[edit]

Merrimack was founded by a group of scientists from MIT and Harvard University in 2000.[3]

In 2016, Merrimack had 426 full-time employees, 103 of which had an MD or PhD.[3]

In October 2016, CEO Robert Mulroy resigned and the company announced they would be laying off 20% of its employees.[4] In January 2017, interim CEO Gary Crocker resigned and the board of directors appointed Richard Peters to be president and CEO. Peters previously worked at Sanofi and was a faculty member at Harvard University.[5]

In January 2017, French pharmaceutical company Ipsen announced they would be purchasing Onivyde from Merrimack for approximately $1 billion.[6] Following the close of the deal with Ipsen, Merrimack reduced its headcount by about 80%. By May of 2019, Merrimack planned to lay off its entire staff, including the leadership team.[7]

On November 13, 2018, the statistical programming director Songjiang Wang, received "six months in prison and one year supervised released" after a guilty verdict was handed down to Wang from a United States District Judge in July 2018 for securities fraud and conspiracy to commit securities fraud.[8] Also on December 20, 2019, the United States Securities and Exchange Commission charged Wang with Insider trading.[9]

On May 10, 2024, Merrimack announced that the stockholders at a Special Meeting held that day approved the adoption of a Plan of Dissolution. The Board of Directors declared a liquidating cash dividend in the amount of $15.10 per share, expected to be paid on or about May 17, 2024. Merrimack’s Common Stock would continue to trade on NASDAQ through May 17, 2024 and thereafter delist from NASDAQ on May 20, 2024.[10]

## Pipeline

[edit]

Merrimack has four drugs in clinical development.

* MM-302 – HER2 targeting antibody-drug conjugate
* MM-121 (seribantumab) – anti-HER3 monoclonal antibody
* MM-141 (istiratumab) – IGF-1R and HER3 bispecific monoclonal antibody
* MM-151 – anti-EGFR mixture of monoclonal antibody

## References

[edit]

1. ^ "Investors - Merrimack".
2. ^ "Onivyde pegylated liposomal EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 19 June 2020.
3. ^ a b "Merrimack - Annual Report". Archived from the original on 2017-02-03. Retrieved 2017-02-02.
4. ^ Jamerson, Joshua (3 October 2016). "Merrimack Pharmaceuticals Cuts Jobs; CEO Resigns Amid Restructuring Effort". Wall Street Journal.
5. ^ "Merrimack - Current Report". Archived from the original on 2017-02-03. Retrieved 2017-02-02.
6. ^ "Ipsen to buy some Merrimack assets for about $1 billion". Reuters. 9 January 2017.
7. ^ "Merrimack to Lay Off Remaining Execs and Staff, Sell Assets". BioSpace. 2019-05-31. Retrieved 2024-10-22.
8. ^ "Former Biopharma Statistical Programmer Sentenced for Insider Trading". United States Department of Justice. November 13, 2018. Retrieved December 20, 2019.
9. ^ "Former Biopharmaceutical Executive Charged with Insider Trading". U.S. Securities and Exchange Commission. December 20, 2019. Retrieved December 20, 2019.
10. ^ "Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock". May 10, 2024. Retrieved October 22, 2024.

* v
* t
* e

Pharmaceutical companies of the United States

Current|

* Abbott Laboratories
* AbbVie Inc.
* Acorda Therapeutics
* Advaxis
* Alcon
* Alexion
* Alnylam
* Amgen
* Amneal Pharmaceuticals
* Avax Technologies
* Baxter
* BioCryst
* Biogen
* Bioverativ
* Biovest
* Biovista
* Bristol Myers Squibb
* Ceragenix
* Combe
* CytoSport
* CytRx
* Danco Laboratories
* Eli Lilly
* Galena Biopharma
* Genentech
* Gilead Sciences
* Ionis
* Institute for OneWorld Health
* Intercept
* Johnson & Johnson
* Ethicon
* Janssen Biotech
* McNeil Consumer Healthcare
* Ortho-McNeil
* Kinetic Concepts
* McKesson
* Melinta Therapeutics
* Melior Discovery
* Mentholatum
* Merck & Co.
* Merrimack Pharmaceuticals
* Myriad Genetics
* Moderna
* Northwest Biotherapeutics
* Norwich Pharma
* NovaBay
* Organon
* Ovation
* Pfizer
* Hospira
* Searle
* Pharmaceutical Product Development
* Prasco Laboratories
* Procter & Gamble
* Proteon Therapeutics
* Purdue Pharma
* Quark
* Regeneron
* RespireRx
* Sarepta Therapeutics
* Sheffield
* Spectrum
* Tec Laboratories
* Titan
* Trevena Inc
* Ultragenyx
* Upsher-Smith
* Ventria Bioscience
* Vertex
* Viatris
* West Pharmaceutical Services

Former|

| Tax inversion|

* Actavis (Ireland, 2013)
* Alkermes (Ireland, 2011)
* Allergan (Ireland, 2015)
* Covidien (Ireland, 2007)
* Endo International (Ireland, 2014)
* Horizon Therapeutics (Ireland, 2014)
* Jazz Pharmaceuticals (Ireland, 2012)
* Mallinckrodt (Ireland, 2013)
* Perrigo (Ireland, 2013)
* Bausch Health (Canada, 2010)

|

Other|

* Alza
* Allergan, Inc.
* Amylin
* ARIAD
* Barr
* Biolex
* Bradley
* CancerVax
* Cephalon
* CoTherix
* Cubist
* Cutter Laboratories
* DNAPrint Genomics
* Epix
* Forest Laboratories
* Genta
* ImClone Systems
* ISTA
* King
* KV
* Leiner Health Products
* Martek Biosciences
* Massengill
* Miles Laboratories
* Mylan
* Naurex
* Nereus
* Nuvelo
* Ortho
* OSI
* Parke-Davis
* Repros Therapeutics
* Qualitest
* Rib-X
* Schering-Plough
* Smith, Kline & French
* Sterling Drug
* Tanox
* TAP
* Trubion
* Upjohn
* Verus
* ViroPharma
* Wyeth
* Zonite

* List of pharmaceutical companies

*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template